2Nicholson RI, Gec JM, Harper ME. EGFR and cancer prognosis[J]. Eur J Cancer,2001,37(Suppl 4) :S9 - 5.
3Fukuoka M,Yano S,Giaccone G,et al. Final results from a phose Ⅱ trial of ZD1839(lressa) for patients with advanced non- small- cell lung cancer (IDEAL1) [J]. Proc Am Soc Clin Oncol,2002,21:298A.
4Kris RB, Natale RS, Herbst TJ, et al. A phase Ⅱ trial of ZD1839(lressa) in advanced non- small - cell lung cancer (NSCLC) patients who had failed platinum and docetaxel- based regimens (IDEAL 2)[J]. Proc Am Soc Clin Oncol, 2002,21:292A.
5Giaccone G, Johnson DH, Manegold C, et al. A phose Ⅲ clinical trial of ZD1839( 'Iressa' ) in combination with gemcitabine and cisplatin in chemotherapy - na? ve patients with advanced non- small cell lung cancer (INTACT1 )[J]. Ann Oncel,2002,13 (Suppl 5) :2.
6Johnson DH, Herbst R, Giaccone g, et al. ZD1839( 'Iressa' ) in combination with paclitaxel and carboplatin in lung cancer (NSCLC):Results from a phase Ⅲ clinical trial(INTACT2)[J]. Ann Oncel,2002,13 (Suppl 5) :127.
5WHO handbook for reporting results of cancer treatment [M].Geneva (Switzerland):World Health Organization,1979.
6Duffaud F,Therasse P.New guidelines to evaluate the response to treatment in solid tumors[J].Bull Cancer,2000,87(12):869-870.
7James K,Eisenhauer E,Christian M,et al.Measuring response in solid tumors:unidimensional versus bidimensional measurement[J].J Natl Cancer Inst,1999,91(6):523-528.
8Mazumdar M,Smith A,Schwartz LH.A statistical simulation study finds discordance between WHO criteria and RECIST guideline[J].J Clin Epidemiol,2004,57(4):358-365.
9Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors [J].J Natl Cancer Inst,2000,92(3):179-181.
10Werner-Wasik M,Xiao Y,Pequignot E,et al.Assessment of lung cancer response after nonoperative therapy:tumor diameter,bidimensional product,and volume.A serial CT sean-based study[J].Int J Radiat Oncol Biol Phys,2001,51(1):56-61.
